

## Original Article

# N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement

Philippe M. Adjagba,<sup>1,2</sup> Laurent Desjardins,<sup>1,3</sup> Anne Fournier,<sup>1</sup> Linda Spiegelblatt,<sup>4</sup> Martine Montigny,<sup>5</sup> Nagib Dahdah<sup>1</sup>

<sup>1</sup>*Division of Pediatric Cardiology, Department of Pediatrics, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada;* <sup>2</sup>*Department of Cardiology, Hopital de la Mère et de l'Enfant-Lagune, Cotonou, Bénin;* <sup>3</sup>*School of Medicine, McGill University;* <sup>4</sup>*Department of Pediatrics, Maisonneuve Rosemont Hospital, Montréal;* <sup>5</sup>*Department of Cardiology, Cité-de-la-Santé Hospital, Laval, Quebec, Canada*

**Abstract** *Background:* We have lately documented the importance of N-terminal pro-brain natriuretic peptide in aiding the diagnosis of Kawasaki disease. *Objectives:* We sought to investigate the potential value of N-terminal pro-brain natriuretic peptide pertaining to the prediction of coronary artery dilatation (Z-score >2.5) and/or of resistance to intravenous immunoglobulin therapy. We hypothesised that increased serum N-terminal pro-brain natriuretic peptide level correlates with increased coronary artery dilatation and/or resistance to intravenous immunoglobulin. *Methods:* We carried out a prospective study involving newly diagnosed patients treated with 2 g/kg intravenous immunoglobulin within 5–10 days of onset of fever. Echocardiography was performed in all patients at onset, then weekly for 3 weeks, then at month 2, and month 3. Coronary arteries were measured at each visit, and coronary artery Z-score was calculated. All the patients had N-terminal pro-brain natriuretic peptide serum level measured at onset, and the Z-score calculated. *Results:* There were 109 patients enrolled at  $6.58 \pm 2.82$  days of fever, age  $3.79 \pm 2.92$  years. High N-terminal pro-brain natriuretic peptide level was associated with coronary artery dilatation at onset in 22.2 versus 5.6% for normal N-terminal pro-brain natriuretic peptide levels (odds ratio 4.8 [95% confidence interval 1.05–22.4];  $p = 0.031$ ). This was predictive of cumulative coronary artery dilatation for the first 3 months ( $p = 0.04$ – $0.02$ ), but not during convalescence at 2–3 months (odds ratio 1.28 [95% confidence interval 0.23–7.3];  $p =$  non-significant). Elevated N-terminal pro-brain natriuretic peptide levels did not predict intravenous immunoglobulin resistance, 15.3 versus 13.5% ( $p = 1$ ). *Conclusion:* Elevated N-terminal pro-brain natriuretic peptide level correlates with acute coronary artery dilatation in treated Kawasaki disease, but not with intravenous immunoglobulin resistance.

Keywords: Kawasaki disease; prediction; coronary artery involvement; N-terminal pro-brain natriuretic peptide; predictive value

Received: 25 July 2014; Accepted: 16 November 2014; First published online: 29 December 2014

**K**AWASAKI DISEASE IS THE MAIN AETIOLOGY OF acquired coronary artery disease in childhood.<sup>1</sup> It typically affects pre-school children, but may be diagnosed later on.<sup>2</sup> Although no definite aetiology is known, Kawasaki disease seems to cause a transitory dysregulation of the immune system,

triggered by unknown common infection(s) in children who have a genetic predisposition.<sup>3,4</sup> Coronary artery complications of Kawasaki disease vary from mild transitory dilatation to severe multi-layer destruction of the coronary arterial wall causing aneurysmal deformation.<sup>5</sup>

Although intravenous immunoglobulin remains the most effective therapy of Kawasaki disease,<sup>6</sup> 10–20% of treated patients may not respond to such therapy,<sup>7,8</sup> as witnessed by the persistence or the recurrence of fever. These patients are at an even greater risk to

Correspondence to: N. Dahdah, MD, FACC, FASE, FRCPC, Division of Pediatric Cardiology, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, 3175, Côte Sainte-Catherine, Montréal, QC H3T 1C5, Canada. Tel: 514 345 4931, ext 5403; Fax: 514 345 4896; E-mail: nagib.dahdah.hsj@ssss.gouv.qc.ca

develop coronary artery complications<sup>7,8</sup>, requiring an additional dose of intravenous immunoglobulin as well as other anti-inflammatory medications.

Given the importance of coronary artery disease, it is crucial to have diagnostic tools to identify acute cases and treat them quickly with intravenous immunoglobulin in the 10-day window period from the onset of symptoms.<sup>9</sup> Unfortunately, the diagnosis of Kawasaki disease is still based on clinical criteria without reliable biomarkers for diagnostic certainty. Biomarkers are even more necessary in the context of incomplete forms of the disease. It is in this context that our group investigated the utility of N-terminal pro-brain natriuretic peptide, a natriuretic peptide, in diagnosing Kawasaki disease.

Natriuretic peptides such as B-type natriuretic peptide are natural diuretics secreted by the myocardium, especially in situations of increased intracardiac pressure and wall stress.<sup>10</sup> The pre-probrain natriuretic peptide, the precursor of brain natriuretic peptide, is a peptide composed of 134 amino acids secreted by cardiomyocytes and cleaved during the first liver passage into probrain natriuretic peptide and an inactive peptide. Probrain natriuretic peptide is then cleaved into an active peptide, brain natriuretic peptide, and an inactive metabolite, N-terminal pro-brain natriuretic peptide.<sup>11</sup> With an improved stability and a longer half-life, N-terminal pro-brain natriuretic peptide (60–120 minutes) was found to be a better biomarker for the diagnosis and prognosis of Kawasaki disease over brain natriuretic peptide (20–30 minutes),<sup>12,13</sup> especially in the case of incomplete forms.<sup>14</sup> In fact, unlike N-terminal pro-brain natriuretic peptide, brain natriuretic peptide could not discriminate between Kawasaki disease and febrile controls. Several series report the use of N-terminal pro-brain natriuretic peptide for diagnosis<sup>15–19</sup> and prognosis of Kawasaki disease, including the presence of coronary dilatation<sup>20,21</sup> and resistance to intravenous immunoglobulin.<sup>22–24</sup>

Despite the growing interest in natriuretic peptides with respect to Kawasaki disease, very few publications have utilised age-related values<sup>25</sup> or age-adjusted Z-values<sup>15</sup> of N-terminal pro-brain natriuretic peptide. In this study, we have set out to investigate the hypothesis that suggests that elevated age-adjusted N-terminal pro-brain natriuretic peptide serum levels at the onset of Kawasaki disease correlate with coronary artery dilatation. The secondary objective was to verify its utility in predicting responsiveness to intravenous immunoglobulin.

## Materials and methods

In this prospective study, consecutive patients were recruited with parental consent at the onset of

Kawasaki disease up to 10 days after the onset of fever. The blood samples were collected before therapy in all cases. Subsequently, serum N-terminal pro-brain natriuretic peptide level was measured using electrochemiluminescence immunoassay template (Roche Diagnostics, Rotkreuz, Switzerland), and Z-values were calculated based on age.<sup>15</sup> Coronary arteries were measured and the Z-values were calculated based on body surface area<sup>26</sup> at onset (W0), weekly for 3 weeks (W1, W2, and W3) for the sub-acute period, and at 2 months (M2) and at 3 months (M3) for the convalescence period. Left and right coronary artery measurements were carried out by experienced echocardiography technicians blinded to the N-terminal pro-brain natriuretic peptide status. The intraluminal diameters of coronary artery segments were measured from inner edge-to-inner edge. The left main coronary artery was measured midway between the ostium and the bifurcation of the circumflex artery and left anterior descending coronary artery in the parasternal short-axis view. The right coronary artery measurements were obtained 3–5 mm distal to its origin in the parasternal short-axis view. In the case of coronary artery ectasia or aneurysms, the portion with the largest diameter was measured instead.<sup>26</sup> Coronary Z-value of 2.5 was the cut-off for coronary artery dilation, following the official recommendations by the American Heart Association.<sup>27</sup> Left ventricular shortening fraction was calculated at onset and during convalescence, that is, 2–3 months after onset. The shortening fraction was then adjusted for age,<sup>28</sup> expressed as a Z-value, and compared between individuals with normal or elevated N-terminal pro-brain natriuretic peptide.

Patients were divided into two groups based on N-terminal pro-brain natriuretic peptide Z-values, those with elevated (Z-value > 2.0) and those with normal N-terminal pro-brain natriuretic peptide levels (Z-value ≤ 2.0).<sup>15</sup>

All patients received intravenous immunoglobulin (2 g/kg) at diagnosis, irrespective of their N-terminal pro-brain natriuretic peptide status. A second dose of intravenous immunoglobulin (2 g/kg) was administered 36 hours later in cases of persistent or recurrent fever. Patients who were resistant to the second course of intravenous immunoglobulin received a third course (1 g/kg) in addition to corticosteroids. Anti-inflammatory dose of amino salicylic acid (80–100 mg/kg) was initiated at diagnosis, followed by anti-platelet dose (3–5 mg/kg) from resolution of fever for 3 months or until resolution of coronary artery dilatation, whichever was longer.

Continuous data were expressed as mean ± standard deviation, qualitative data were represented in proportions, percentages, and median [range], whenever applicable. Data analysis was performed


with SigmaStat 3.5 (Systat, Software Inc., Erkrath, Germany). Odds ratios were calculated with the 95th percentile confidence interval. Correlation analyses were performed for the potential association between N-terminal pro-brain natriuretic peptide status on one hand and coronary artery dilatation, resistance to intravenous immunoglobulin, and left ventricle systolic function on the other hand. A  $p < 0.05$  was considered statistically significant.

**Results**

There were 109 patients included during the study period between November, 2005 and March, 2012. The male/female ratio was 1.18/1. Age at diagnosis was  $3.79 \pm 2.92$  years, with the diagnosis established at  $6.58 \pm 2.82$  days from the onset of fever. Of the 109 patients, 72 (66%) had elevated N-terminal pro-brain natriuretic peptide levels at diagnosis, with an average N-terminal pro-brain natriuretic peptide serum level of  $3128.4 \pm 5985.8$  versus  $249.9 \pm 117.7$  pg/ml in those with normal levels ( $p = 0.004$ ). Accordingly, the comparative N-terminal pro-brain natriuretic peptide Z-score was  $3.4 \pm 1.2$  versus  $1.2 \pm 0.7$  ( $p < 0.001$ ). Comparative basic characteristic data are summarised in Table 1.

Among the total study population, 18 (16.7%) were diagnosed with coronary artery dilatation at onset. Based on N-terminal pro-brain natriuretic peptide categorisation, there was a significantly higher proportion of such cases with elevated N-terminal

pro-brain natriuretic peptide (22.2%), compared with those with normal N-terminal pro-brain natriuretic peptide (5.6%), with an odds ratio of 4.8 [95% confidence interval 1.05–22.4];  $p = 0.03$ . The cumulative proportion with coronary artery dilatation from onset to convalescence was 26.4 versus 8.1%, respectively, with an odds ratio of 4.06 [95% confidence interval 1.12–14.8];  $p = 0.025$  (Fig 1). The receiver operator characteristics analysis was similarly favourable for the prediction of coronary artery dilatation. The area under the curve of  $0.716 \pm 0.059$  [95% confidence interval 0.601–0.831;  $p = 0.004$ ] provided N-terminal



**Figure 1.** Relationship between N-terminal pro-brain natriuretic peptide (NT-proBNP) serum level upon diagnosis (elevated if Z-score >2.0) and the prevalence of coronary artery dilatation at onset (W0), sub-acute (W3), and convalescent phases (M2–M3). Cumulative prevalence during acute and sub-acute period (W0–W3) and onset to convalescence (W0–M3) are also represented.

Table 1. Anthropometric and basic characteristics of study subjects at diagnosis.

	All subjects	High NT-proBNP	Normal NT-proBNP	p-value*
Number	109	72	37	na
Age (years)	$3.6 \pm 2.5$	$3.4 \pm 2.8$	$3.9 \pm 1.9$	0.268
Weight (kg)	$15.7 \pm 7.5$	$15.6 \pm 8.7$	$15.8 \pm 4.5$	0.845
Height (cm)	$97.4 \pm 20.8$	$95.9 \pm 23.2$	$100.3 \pm 15.1$	0.237
BSA (m <sup>2</sup> )	$0.65 \pm 0.21$	$0.64 \pm 0.23$	$0.66 \pm 0.14$	0.532
Male/female	64/45	45/27	19/18	0.307
iKD/cKD	44/65	31/41	13/24	0.537
Clinical criteria	5 [1–6]	5 [1–6]	5 [3–6]	0.250
Day of IVIG from onset of fever	$7.1 \pm 5.3$	$6.6 \pm 2.6$	$8.0 \pm 8.4$	0.311
Delayed diagnosis/therapy [n (%)]**	8/109 (7.3%)	5/72 (6.9%)	3/37 (8.1%)	0.882
White blood cell (10 <sup>9</sup> /L)	$14.3 \pm 6.5$	$14.6 \pm 6.9$	$13.8 \pm 5.6$	0.510
Platelet count (10 <sup>9</sup> /L)	$357 \pm 169$	$342 \pm 176$	$384 \pm 153$	0.218
Haematocrit (%)	$31.3 \pm 4.5$	$30.8 \pm 5.0$	$32.2 \pm 3.4$	0.145
C-reactive protein (mg/L)	$120.8 \pm 106 \pm 4$	$138.5 \pm 116.9$	$89.3 \pm 76.0$	0.024
Sedimentation rate (mm/h)	$55.3 \pm 38.9$	$55.7 \pm 47.9$	$54.8 \pm 18.2$	0.918
Serum albumin (g/L)	$29.4 \pm 7.2$	$27.9 \pm 6.9$	$32.4 \pm 6.9$	0.007
Serum protein (g/L)	$63.2 \pm 9.8$	$62.9 \pm 11.2$	$63.7 \pm 6.8$	0.705

IVIG = intravenous immunoglobulin; NT-proBNP = N-terminal pro-brain natriuretic peptide

\*p-value comparative between patients with high and normal NT-proBNP Z-scores

\*\*Presentation or diagnosis after day 10 from onset of fever. iKD, patients with incomplete diagnostic criteria for Kawasaki disease; cKD, patients with complete diagnostic criteria

Table 2. Various NT-proBNP prediction levels of CAD at onset of Kawasaki disease.

	Sensitivity For CAD at onset	Specificity		NT-proBNP Correlates (pg/ml)***
		Z-score*	Raw level**	
Z > 2.0	0.889	0.378	0.444	530
Z > 2.25	0.778	0.500	0.500–0.567	591–657
Z > 2.5	0.772	0.589	0.567	660

CAD = coronary artery dilatation; NT-proBNP = N-terminal pro-brain natriuretic peptide

\*Specificity based on NT-proBNP Z-scores

\*\*Specificity based on NT-proBNP plasma concentrations

\*\*\*NT-proBNP correlates with the related sensitivity in column 2

pro-brain natriuretic peptide Z-score-related specificity and sensitivity levels of 0.889–0.772 and 0.378–0.589, respectively (Table 2). As one cannot determine a single cut-off serum level based on a specific Z-score of N-terminal pro-brain natriuretic peptide, we established the correlates of three Z-score values (2.0, 2.25, and 2.5) corresponding to similar sensitivity values – area under the curve of  $0.720 \pm 0.057$ ;  $p = 0.003$ . Accordingly, these serum levels varied between 530 and 660 pg/ml, with specificity values comparable with Z-score-based parameters (Table 2). In contrast, the coronary artery dilatation distribution according to the published upper-limit for age of N-terminal pro-brain natriuretic peptide did not reach statistical significance (19.0 versus 8.3%;  $p = 0.35$ ).

Cumulative coronary artery dilatation between onset and 3-month follow-up remained significantly predictable by an abnormal N-terminal pro-brain natriuretic peptide Z-score (26.4 versus 8.1%,  $p = 0.025$ ). Nevertheless, there was no predictable value ( $p = 1.0$ ) on the convalescent phase alone, 2–3 months after onset, as witnessed by an odds ratio of 1.28 [0.23–7.30].

Left ventricle shortening fraction negatively correlated with N-terminal pro-brain natriuretic peptide level (Fig 2), with lower intercept at onset compared with the convalescent phase of the disease ( $-0.626 \pm 0.359$  and  $1.174 \pm 0.377$ , respectively;  $p < 0.001$ ), but with similar slopes ( $-0.309 \pm 0.120$  and  $-0.287 \pm 0.125$ , respectively;  $p = 0.323$ ). In addition, the fractional shortening Z-value was significantly lower at onset and at convalescence in patients with high N-terminal pro-brain natriuretic peptide levels compared with those with normal N-terminal pro-brain natriuretic peptide levels ( $-1.77 \pm 1.94$  and  $-0.81 \pm 1.31$ , respectively;  $p = 0.014$ ). These values (Fig 3) increased significantly at convalescence in both groups to  $0.122 \pm 1.83$  and  $0.98 \pm 1.75$ , respectively ( $p < 0.001$  for both).

The secondary study analysed the overall effectiveness of therapeutic response to intravenous immunoglobulin and the regression of coronary




Figure 2.

Scatter plot with linear regression depicts lower left ventricle fractional shortening with higher N-terminal pro-brain natriuretic peptide (NT-proBNP), both at onset (circles) and upon evaluation during convalescence (triangles).




Figure 3.

Left ventricle shortening fraction Z-value according to serum N-terminal pro-brain natriuretic peptide (NT-proBNP) status. High NT-proBNP is associated with significantly lower shortening fraction at onset. Despite significant improvement at convalescence, left ventricle contractility remained significantly lower than in cases with normal NT-proBNP.

Table 3. Distribution of the presence (CAL+) or the absence (CAL-) of coronary artery lesions according to the responsiveness to IVIG, displayed in accordance with the timing from diagnosis (onset), cumulative with the sub-acute phase (onset–sub-acute), at 2–3 months (convalescence), and cumulatively up to 3 months (onset–convalescence).

		IVIG responsive	IVIG resistant	p-value
Onset	CAL+/CAL-	13/79 (14.1%)	5/11 (31.2%)	0.096
Onset–sub-acute	CAL+/CAL-	15/78 (16.1%)	6/10 (37.5%)	0.055
Convalescence	CAL+/CAL-	7/62 (10.1%)	3/9 (25.0%)	0.163
Onset–convalescence	CAL+/CAL-	16/77 (17.2%)	6/10 (37.5%)	0.088

IVIG = intravenous immunoglobulin

lesions at this specific time. In this respect, an elevated N-terminal pro-brain natriuretic peptide level was not predictive of responsiveness versus resistance to intravenous immunoglobulin, either according to the Z-score values (15.3 versus 13.5%,  $p = 1.0$ ) or the upper-limit for age (15.5 versus 12.0%;  $p = 0.55$ ). The receiver operating characteristic analysis did not yield a better prediction level for intravenous immunoglobulin resistance, with an area under the curve of  $0.577 \pm 0.085$  [95% confidence interval 0.41–0.74] ( $p = 0.329$ ). From another perspective, the proportion of patients who developed coronary artery lesions tended to be higher in cases who were resistant to intravenous immunoglobulin, but without reaching statistical significance (Table 3). These proportions varied from 31.25 versus 14.13%, at onset ( $p = 0.096$ ), to 25 versus 10.5%, at convalescence ( $p = 0.163$ ).

## Discussion

### *Coronary dilatation and N-terminal pro-brain natriuretic peptide*

The prevalence of coronary artery dilatation in our series was 5.6% in normal N-terminal pro-brain natriuretic peptide patients and 22.2% in those with elevated levels of N-terminal pro-brain natriuretic peptide. This is reminiscent of the prevalence of coronary artery aneurysms and ectasia before and following the era of intravenous immunoglobulin therapy, that is, 15–25% in the absence of intravenous immunoglobulin therapy and 5% in cases where intravenous immunoglobulin is administered within the 10-day effective therapeutic window period.<sup>9,29</sup> Our findings using N-terminal pro-brain natriuretic peptide Z-score stratification are concordant with a recent report on absolute values, where patients with coronary artery dilatation had serum measurements of  $2611 \pm 1699$  pg/ml compared with  $1073 \pm 1427$  pg/ml in those who did not exhibit coronary artery dilatation ( $p = 0.03$ ).<sup>30</sup> It is also in agreement with a single cut-off value of 1300 pg/ml approach used by another group<sup>31</sup> who identified the 19 patients who developed a coronary artery lesion out of a total of

80 individuals who had received intravenous immunoglobulin. According to the latter study, such a cut-off value provides 95% sensitivity with a specificity of 85%. Our group had identified the cut-off value of 190 pg/ml to support the diagnosis of acute Kawasaki disease, but not for the likelihood of coronary artery involvement. Based on our work<sup>14,15</sup> and those of others,<sup>32</sup> however, the use of a fixed cut-off value of N-terminal pro-brain natriuretic peptide serum level is to be avoided because of the wide variation of normal values of N-terminal pro-brain natriuretic peptide during early childhood.<sup>25</sup> Alternatively, when we applied suggested age-related values, the analysis did not reach statistical significance, despite a similar trend in the prevalence rates. Not surprisingly, the 190 pg/ml diagnostic cut-off value was not predictive of coronary artery lesions or of intravenous immunoglobulin resistance. This may be interpreted as the need for much higher values (1300 pg/ml) to identify patients at risk for coronary artery involvement and intermediate values (800 pg/ml) to identify the risk for intravenous immunoglobulin resistance.<sup>31</sup> In our study, we determined the cut-off values using various degrees of the N-terminal pro-brain natriuretic peptide Z-score, a value  $>2.25$ – $2.5$  providing a better specificity while preserving an acceptable sensitivity compared with the diagnostic cut-off Z-value of 2.0. For the sake of comparison, serum concentrations of N-terminal pro-brain natriuretic peptide corresponding to coronary artery involvement detection (530–660 pg/ml) were lower than the previously reported 1300 pg/ml. Nevertheless, knowing the wide variation of N-terminal pro-brain natriuretic peptide serum concentration with age in children, we prefer the Z-score approach to using actual measurements.

Therapeutic response to intravenous immunoglobulin in Kawasaki disease must be viewed from the following two perspectives: one pertaining to the reduction of fever and inflammation and another pertaining to the protection against coronary artery involvement, mainly persistent dilatation and aneurysm formation. As intravenous immunoglobulin is well known to reduce the likelihood of coronary

artery involvement, it was less likely that we would detect new onset coronary artery dilatation in children receiving intravenous immunoglobulin within the first 10 days of fever. This is probably the reason why N-terminal pro-brain natriuretic peptide was not predictive of additional coronary artery involvement in the sub-acute and convalescence period. It was, however, significantly associated with the cumulative prevalence. A reduction in N-terminal pro-brain natriuretic peptide serum level during convalescence<sup>14,18,33</sup> is probably reflective of a settled myocardial inflammatory status.

#### *Intravenous immunoglobulin resistance and N-terminal pro-brain natriuretic peptide*

In general 10–20% of patients are potentially non-responders to initial intravenous immunoglobulin.<sup>7,8</sup> In a series of 129 patients,<sup>21</sup> 107 (83%) responded completely to a single intravenous immunoglobulin course, and 22 patients (17%) required re-treatment due to persistent fever in 14 and re-crudescent fever in 8. In our series, and despite an apparent trend, the presence or the absence of coronary artery lesions was not significantly associated with the responsiveness to intravenous immunoglobulin, at either stage of the disease. A similar trend – 22.73% in resistant patients versus 14.16% in responders to intravenous immunoglobulin, with non-significant p-value – was reported by another group.<sup>22</sup> In another publication, however, the trend was statistically significant (31.8 versus 2.8%,  $p < 0.001$ ).<sup>21</sup> The association of an increased risk for coronary artery involvement makes it important to establish a predictive factor. To that effect, resistance to intravenous immunoglobulin has been found to be associated not with the serum level of N-terminal pro-brain natriuretic peptide at onset but with a persistent high serum level following intravenous immunoglobulin.<sup>21</sup> This, in part, goes along with our findings, as onset N-terminal pro-brain natriuretic peptide serum level was not found to be predictive of intravenous immunoglobulin resistance on one hand. On the other hand, our data do not support the relationship of a drop in N-terminal pro-brain natriuretic peptide following initial intravenous immunoglobulin. The discriminative pre-intravenous immunoglobulin and post-intravenous immunoglobulin serum concentrations of N-terminal pro-brain natriuretic peptide seem to be reproduced in a few other series, where a decrease of N-terminal pro-brain natriuretic peptide to the normal range was recorded in patients who were responsive to intravenous immunoglobulin in comparison with resistant patients.<sup>21</sup> In a more recent retrospective study including 135 patients, there were 16.3% non-responders to intravenous immunoglobulin. The N-terminal pro-brain

natriuretic peptide level was  $2465.36 \pm 3293.24$  pg/ml in these patients versus  $942.38 \pm 1293.48$  pg/ml in the responders ( $p < 0.01$ ).<sup>22</sup> In this study, the predictive cut-off point was 1093 pg/ml, with an odds ratio of 7.2 [95% confidence interval 4.2–6.9]. This was not the only group to report such predictive values, with another study having a cut-off value of 800 pg/ml, 71% sensitivity, and 62% specificity.<sup>31</sup>

#### *Myocardial involvement*

Left ventricular dysfunction has been previously described in acute Kawasaki disease.<sup>34</sup> Correlation with elevated N-terminal pro-brain natriuretic peptide level has recently been described,<sup>35</sup> corresponding with our findings. Although detectable in cases with normal N-terminal pro-brain natriuretic peptide levels, low left ventricular shortening fraction Z-score is more depressed in cases with high N-terminal pro-brain natriuretic peptide levels. Despite recovery at 2–3 months, left ventricular shortening fraction Z-score remained significantly lower in cases with high N-terminal pro-brain natriuretic peptide levels compared with those with normal N-terminal pro-brain natriuretic peptide at onset. Long-term assessment of myocarditis is, therefore, worth studying in the future.

#### **Study limitations**

In this study, all subjects received intravenous immunoglobulin upon diagnosis. It is, therefore, impossible to report the actual N-terminal pro-brain natriuretic peptide predictive value of coronary artery dilatation with respect to the natural history of Kawasaki disease. Furthermore, it is now ethically impossible to conduct such a study where patients would be denied such an effective therapy. In this study, we failed to demonstrate the potential utility of N-terminal pro-brain natriuretic peptide in detecting patients resistant to intravenous immunoglobulin. Although our results are close to previous reports, it is possible that our sample size is under-powered for this aim.

#### **Conclusions**

N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery dilatation and reduced left ventricular contractility in patients who had received intravenous immunoglobulin within the therapeutic window. Using the definition of an elevated Z-score  $> 2$  provides a better standardisation than absolute values in an age group where normal levels vary significantly. At this point, our data do not support previously reported series in

terms of the prediction of intravenous immunoglobulin resistance.

### Acknowledgements

Philippe Mahouna Adjagba is supported with a fellowship grant from Fondation CHU Ste-Justine.

### Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

### Conflicts of Interest

None.

### References

1. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on population and prevention science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2006; 114: 2710–2738; [Epub ahead of print].
2. Manlhiot C, Yeung RS, Clarizia NA, Chahal N, McCrindle BW. Kawasaki disease at the extremes of the age spectrum. *Pediatrics* 2009; 124: e410–e415; [Epub ahead of print].
3. Burns JC, Newburger JW. Genetics insights into the pathogenesis of Kawasaki disease. *Circ Cardiovasc Genet* 2012; 5: 277–278.
4. Onouchi Y. Genetics of Kawasaki disease: what we know and don't know. *Circ J* 2012; 76: 1581–1586; [Epub ahead of print].
5. Tsuda E, Kamiya T, Ono Y, Kimura K, Kurosaki K, Echigo S. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. *Pediatr Cardiol* 2005; 26: 73–79.
6. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. *N Engl J Med* 1991; 324: 1633–1639.
7. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. *Pediatr Cardiol* 2003; 24: 145–148; [Epub ahead of print].
8. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. *J Pediatr* 2000; 137: 172–176.
9. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics* 2004; 114: 1708–1733.
10. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. *Lancet* 2003; 362: 316–322.
11. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: natriuretic peptide receptors. *J Hypertens* 1992; 10: 1111–1114.

12. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. *Eur J Heart Fail* 2004; 6: 261–268.
13. Tang WH. B-type natriuretic peptide: a critical review. *Congest Heart Fail* 2007; 13: 48–52.
14. Dahdah N, Siles A, Fournier A, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. *Pediatr Cardiol* 2009; 30: 810–817; [Epub ahead of print].
15. McNeal-Davidson A, Fournier A, Spigelblatt L, et al. Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. *Pediatr Int* 2012; 54: 627–633; [Epub ahead of print].
16. Lee DW, Kim YH, Hyun MC, Kwon TC, Lee SB. NT-proBNP as a useful tool in diagnosing incomplete Kawasaki disease. *Korean Pediatr* 2010; 53: 519–524.
17. Dahdah N, Fournier A. Natriuretic peptides in Kawasaki disease: the myocardial perspective. *Diagnostics* 2013; 3: 1–12.
18. Kawamura T, Wago M. Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. *Cardiol Young* 2002; 12: 153–158.
19. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. *Pediatr Int* 2000; 42: 241–248.
20. Bang S, Yu JJ, Han MK, et al. Log-transformed plasma level of brain natriuretic peptide during the acute phase of Kawasaki disease is quantitatively associated with myocardial dysfunction. *Korean J Pediatr* 2011; 54: 340–344; [Epub ahead of print].
21. Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. *Korean Circ J* 2011; 41: 379–384; [Epub ahead of print].
22. Kim SY, Han MY, Cha SH, Jeon YB. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study. *Pediatr Cardiol* 2013; 34: 1837–1843; [Epub ahead of print].
23. Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. *Pediatrics* 2012; 129: e17–e23; [Epub ahead of print].
24. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. *J Pediatr* 2011; 158: 831.e3–835.e3; [Epub ahead of print].
25. Nir A, Lindinger A, Rauh M, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. *Pediatr Cardiol* 2009; 30: 3–8; [Epub ahead of print].
26. Dallaire F, Dahdah N. New equations and a critical appraisal of coronary artery Z scores in healthy children. *J Am Soc Echocardiogr* 2011; 24: 60–74; [Epub ahead of print].
27. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics* 2004; 114: 1708–1733.
28. Kampmann C, Wiethoff C, Wenzel A, et al. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. *Heart* 2000; 83: 667–672.
29. Falcini F. Kawasaki disease. *Curr Opin Rheumatol* 2006; 18: 33–38.
30. Kaneko K, Yoshimura K, Ohashi A, Kimata T, Shimo T, Tsuji S. Prediction of the risk of coronary arterial lesions in Kawasaki disease by brain natriuretic peptide. *Pediatr Cardiol* 2011; 32: 1106–1109; [Epub ahead of print].
31. Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease. *J Pediatr* 2013; 162: 1205–1209; [Epub ahead of print].

32. Shiraishi M, Fuse S, Mori T, et al. N-terminal pro-brain natriuretic peptide as a useful diagnostic marker of acute Kawasaki disease in children. *Circ J* 2013; 77: 2097–2101; [Epub ahead of print].
33. Kurotobi S, Kawakami N, Shimizu K, et al. Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. *Pediatr Cardiol* 2005; 26: 425–430.
34. Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. *J Am Coll Cardiol* 2011; 57: 86–92.
35. Sato YZ, Molkara DP, Daniels LB, et al. Cardiovascular biomarkers in acute Kawasaki disease. *Int J Cardiol* 2013; 164: 58–63; [Epub ahead of print].